A Phase 2, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of BHV-7000 in Treatment of Bipolar I Disorder
Latest Information Update: 13 Jun 2025
At a glance
- Drugs BHV-7000 (Primary)
- Indications Bipolar I disorders
- Focus Adverse reactions
- Acronyms Bipolar Mania Study
- Sponsors Biohaven Therapeutics
Most Recent Events
- 08 Jun 2025 Status changed from recruiting to discontinued. Reason the study was stopped: Business Decision.
- 20 Jun 2024 Status changed from not yet recruiting to recruiting.
- 24 May 2024 New trial record